Pharma & Specialty Chemical Standards

Ceritinib, (S)-N-(3,5-difluorophenyl)-3-isopropyl-1-(1-methyl-1H-indazol-5-yl)-1H-pyrazole-4-carboxamide (C22H20F2N6O), is an ATP-competitive tyrosine kinase inhibitor with a molecular weight of 410.43 g/mol. Structurally, it features a pyrazole core linked to an indazole and difluorophenyl moiety. It belongs to the class of anaplastic lymphoma kinase (ALK) inhibitors, targeting ALK-positive non-small cell lung cancer. Ceritinib exhibits moderate lipophilicity (logP ~3.8) and is soluble in DMSO. Its mechanism involves binding to the ATP-binding site of ALK, inhibiting autophosphorylation and downstream signaling pathways, thereby suppressing tumor growth.